Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod with or without HPV vaccination for usual-type vulvar intraepithelial neoplasia
NL-OMON33950Phase 2Withdrawn
- Sponsor
- Erasmus MC
- Start
- Mar 2009
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in vulvar intraepithelial neoplasia (VIN) and human papillomavirus infection comparing HPV vaccine + imiquimod with Placebo vaccination + imiquimod (2 arms). Primary endpoints: Clinical response in VIN lesions, HPV DNA clearance and 1 more. Planned start Mar 2009; status: withdrawn.
02
Drugs
imiquimodhuman papillomavirus vaccine
03
Conditions
vulvar intraepithelial neoplasia (VIN)human papillomavirus infection
Beyond the preview
Go deeper on NL-OMON33950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33950.